• 1
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 2
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
  • 3
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
  • 4
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
  • 5
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
  • 6
    Waiting list candidates [Computer file]. Organ Procurement and Transplantation Network (OPTN). U.S. Dept. of Health and Human Services, Public Health Service, Bureau of Health Resources Development, Division of Organ Transplantation; 2011.
  • 7
    Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21: 55-65.
  • 8
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
  • 9
    Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870-876.
  • 10
    Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006; 38: 497-505.
  • 11
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
  • 12
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
  • 13
    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-874.
  • 14
    Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 2007; 70: 177-187.
  • 15
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
  • 16
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31( Suppl 2): 4-17.
  • 17
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-546.
  • 18
    El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012; 19: 153-160.
  • 19
    Human mortality database, University of California, Berkeley; 2012.
  • 20
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 1318-1324.
  • 21
    Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
  • 22
    Centers for Disease Control and Prevention. Hepatitis surveillance. Hepatitis surveillance/Center for Disease Control 2006 Sept. 1 (Report 61).
  • 23
    Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 2007; 56: 1-24.
  • 24
    Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
  • 25
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
  • 26
    Consumer Price Index Bureau of Labor Statistics USDoL. Washington, D.C: United States Department of Labor; 2010 May 11.
  • 27
    Viral hepatitis surveillance, United States 2010 National Center for HIV SaTPDoHASB. Atlanta, GA: Centers for Disease Control and Prevention; 2010.
  • 28
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
  • 29
    Disease Burden from Viral Hepatitis A, B, and C in the United States Centers for Disease Control and Prevention. Atlanta, GA: Centers for Disease Control; 2010 Nov 15.
  • 30
    National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
  • 31
    Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
  • 32
    Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504.
  • 33
    Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 2007; 167: 166-173.
  • 34
    Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. HEPATOLOGY 2007; 46: 37-47.
  • 35
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
  • 36
    Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874-880.
  • 37
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
  • 38
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36( 5 Suppl 1): S47-S56.
  • 39
    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY 1999; 29: 1215-1219.
  • 40
    Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31( Suppl 1): 18-22.
  • 41
    Chak E, Talal A, Sherman KE, Schiff E, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011; 31: 1090-1101.
  • 42
    Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
  • 43
    McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. HEPATOLOGY 2012; 55: 1344-1355.
  • 44
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
  • 45
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999; 29: 908-914.
  • 46
    Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. HEPATOLOGY 2008; 48: 418-431.
  • 47
    Ries LAG, Young GL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. [NIH Pub.No.07-6215]. 2007. Bethesda, MD, National Cancer Institute, SEER Program.